Crucial transitions in cancer—including tumor initiation, local expansion, metastasis, and
therapeutic resistance—involve complex interactions between cells within the dynamic tumor …

Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of
chemotherapy response associations, including a 19q13.31–33 somatic deletion encoding …

Background The CXC chemokine receptor type 4 (CXCR4)–stromal cell-derived factor-1α (SDF-1α)
axis regulates function and trafficking of immune cells and the tumour …

Purpose We sought to exploit the heterogeneity afforded by patient-derived tumor xenografts
(PDX) to first, optimize and identify robust radiomic features to predict response to therapy …

Cancer proteogenomics promises new insights into cancer biology and treatment efficacy by
integrating genomics, transcriptomics and protein profiling including modifications by mass …

BACKGROUND: Obesity is associated with poorer outcomes in patients with hormone
receptor‐positive breast cancers. This association is not well established for women with triple‐…

Background Radiomics analyses has been proposed to interrogate the biology of tumour as
well as to predict/assess response to therapy in vivo. The objective of this work was to …

The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive
breast cancer (BC) may lead to over or under treatment. We investigated the …

Purpose NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy
as a result of its high immunogenicity. The aim of this study was to explore the potential for NY…

Studies have shown that ALDH1A1 expression in the breast is associated with worse clinical
outcome. ALDH1A1 inactivates cyclophosphamide, which is an integral agent in breast …